Fang 2016.

Methods	Study design: Randomised clinical trial Study duration: February 2014 to February 2015 Duration of follow‐up: 1 year Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by liver biopsy; tumour maximal diameter ≥ 5 cm Age (mean ± SD, range): TACE + RFA: 63.4 ± 5.6 years, 37‐79 years; TACE alone: 62.8 ± 5.2 years, 35‐81 years Male (n/total): TACE + RFA: 16/25; TACE alone: 14/25 Child‐Pugh Class (patients): Class A: 44; Class B: 6
Interventions	TACE + RFA group (n = 25): TACE: Chemotherapeutic drugs: epirubicin, oxaliplatin, and hydroxy camptothecin RFA: Ultrasound‐guided RFA TACE group (n = 25): Chemotherapeutic drugs: epirubicin, oxaliplatin, and hydroxy camptothecin
Outcomes	Tumour response: measured by contrast‐enhanced CT or MRI at 3 days after treatment
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.